Skip to main content

Table 5 Distribution of C4 polymorphisms in Graves' disease patients with or without vitiligo

From: Association between copy number variation of complement component C4 and Graves' disease

Variations Vitiligo P value, individuala
[OR (95%CI), individual]c
P valueb OR (95%CI)d
  No, N (%) Yes, N (%)    
C4 CNV      
4 258 (50.6) 56 (49.1) 0.836 0.002 (Reference)
< 4 97 (19.0) 37 (32.5) 0.002 [1.297 (0.434-3.874)]   1.334 (0.415-4.289)
> 4 155 (30.4) 21 (18.4) 0.011 [0.987 (0.362-2.691)]   1.076 (0.370-3.133)
C4A CNV      
2 330 (64.7) 65 (57.0) 0.133   (Reference)
< 2 52 (10.2) 27 (23.7) 2.650 × 10-4 [5.153 (1.629-16.3000] 0.001 5.579 (1.659-18.763)
> 2 128 (25.1) 22 (19.3) 0.225   1.289 (0.414-4.013)
C4B CNV      
2 310 (60.8) 67 (58.8) 0.751   (Reference)
< 2 112 (22.0) 31 (27.2) 0.267 0.414 1.133 (0.355-3.614)
> 2 88 (17.3) 16 (14.0) 0.487   2.107 (0.687-6.467)
C4 polymorphisms      
A2B2 213 (41.8) 41 (36.0) 0.292 0.03 (Reference)
A2B1 62 (12.2) 16 (14.0) 0.638   0.889 (0.175-4.524)
A3B2 57 (11.2) 7 (6.1) 0.125   0.756 (0.132-4.335)
A2B3 40 (7.8) 4 (3.5) 0.154   1.111 (0.151-8.205)
A3B1 25 (4.9) 7 (6.1) 0.638   1.484 (0.199-11.089)
A1B2 22 (4.3) 12 (10.5) 0.019 [2.035(0.335-12.368)]   2.745 (0.384-19.599)
Other 91 (17.8) 27 (23.7)    3.471 (1.046-11.525)
  1. Abbreviations: GD, Graves' disease; GO, Graves' ophthalmopathy; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.
  2. aIndividual C4 CNVs and polymorphisms between GD patients with or without vitiligo were evaluated by Fisher's exact test using 2 × 2 contingency tables.
  3. b CNV of C4, C4A and C4B between GD patients with or without vitiligo were evaluated by Fisher's exact test using 3 × 2 contingency tables.C4 polymorphisms between GD patients with or without vitiligo were evaluated by Fisher's exact test using 7 × 2 contingency tables. The p value was estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI).
  4. cORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, myxedema and GO.
  5. dORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, myxedema and GO.